Dr. Reddy's Laboratories
Dr. Reddy's Laboratories makes generic medicines, APIs and biosimilars, sold mainly in the US, India, Russia and other emerging markets.
- P/E ~39x (earnings compressed)
- PAT down 35% YoY
- D/E ~0.2, low debt
- USFDA Form 483s at 3 plants
- Promoter 26.6%, no pledge
Updated on 26 Oct 2026 · Data as of 23 Oct 2026
Get this report as a PDF free, straight to your inbox.
Snapshot
- Share price
- ₹1,229.50
- 23 Oct 2026
- 52-week range
- ₹1,135.60 – ₹1,367.03
- All-time peak
- ₹1,394.74
- 21 Aug 2024 · −11.8% from peak
- Dividend yield
- 0.65%
- Price history since
- 1996
- About 30 years of prices
What's happening
Dr. Reddy's reported Q2 FY27 results on 23-Oct-2026: revenue of about Rs 8,671 crore, roughly flat year-on-year, but net profit of Rs 925 crore, down about 35.5% from Rs 1,437 crore a year earlier. The company also took a product recall hit in Canada on its weight-loss drug semaglutide and flagged a shelf-stock adjustment on its generic Revlimid (lenalidomide) business, both weighing on profit. Management says it is targeting a semaglutide device relaunch in Canada around November 2026.
In plain terms
This is an Indian company that sells low-cost versions of medicines whose patents have expired, plus some newer complex drugs, across the US, India and other markets. The tension right now: profit has fallen sharply for three quarters running, but a big chunk of that is one-off charges tied to new product launches (a copy of the popular weight-loss drug semaglutide, and a Canadian product recall) and a pricing adjustment on an older cancer-drug copy, not necessarily a shrinking core business. Whether these charges are truly behind the company or keep recurring as it pushes into more complex, harder-to-make drugs is the open question.
Quarters
Profit has fallen for three straight quarters: Q4 FY26 PAT fell 86% YoY, Q1 FY27 fell 69% YoY (hit by a semaglutide inventory provision), and Q2 FY27 fell 35.5% YoY to Rs 925 crore on revenue of Rs 8,671 crore (nearly flat YoY). These are real rupee declines, not a tiny-base distortion - profit genuinely dropped from roughly Rs 1,437 crore to Rs 925 crore in the same quarter a year apart. Q2 FY27 EBITDA margin was about 20.6%. Management's own framing is that, stripping out the lenalidomide (gRevlimid) shelf-stock hit, the base business grew in double digits - this claim could not be independently verified and should be treated as company commentary rather than a confirmed fact.
Performance
Heads-up on splits: Dr. Reddy's Laboratories has split its shares or issued bonus shares before (most recently 5-for-1 on 28 Oct 2024, 2-for-1 on 28 Aug 2006 and 2-for-1 on 10 Oct 2001). A sudden price drop around a split date is usually just the price adjusting for the extra shares, not a crash.
Share price
−3.3% over 1 year
Returns by period
| Period | Dr. Reddy's Laboratories | Nifty 50 | Cipla |
|---|---|---|---|
| 3 months | +6.8% | −4.9% | −5.2% |
| 1 year | −3.3% | −12.7% | −17.9% |
| 3 years | +13.6% | +18.2% | +18.9% |
| 5 years | +35.9% | +24.7% | +54.6% |
₹100 invested on 25 Oct 2021 became…
- Dr. Reddy's Laboratories₹136
- Nifty 50₹125
- Cipla₹155
Over 1 year the stock is down just 3.3%, actually beating the Nifty (-12.7%) and peer Cipla (-17.9%) in a weak market for pharma. But over 3 years it has returned 13.6%, trailing both the Nifty (18.2%) and Cipla (18.9%), and over 5 years it has returned 35.9% - ahead of the Nifty (24.7%) but well behind Cipla's 54.6%. The stock is down 11.8% from its August 2024 peak of Rs 1,394.74 and currently sits mid-range between its 52-week low (Rs 1,135.6) and high (Rs 1,367). Note: the company did a 1:5 stock split effective 28-Oct-2024 - the price and return figures here are already adjusted for that, so the split is not the cause of any of these moves.
Dividend
Paid in the last 12 months
₹8.00 per share
Dividend yield
0.65%
Dividend yield is the last 12 months of dividends divided by today's share price. A 0.7% yield means every ₹100 of Dr. Reddy's Laboratories shares paid about ₹0.7 in dividends over the past year. Past payouts can change.
Recent dividends
| Date | Per share |
|---|---|
| 10 Jul 2026 | ₹8.00 |
| 10 Jul 2025 | ₹8.00 |
| 16 Jul 2024 | ₹8.00 |
| 11 Jul 2023 | ₹8.00 |
| 11 Jul 2022 | ₹6.00 |
| 9 Jul 2021 | ₹5.00 |
| 13 Jul 2020 | ₹5.00 |
| 15 Jul 2019 | ₹4.00 |
Valuation
The trailing P/E of roughly 39x looks expensive, but why matters more than what: it is inflated mainly because trailing earnings are temporarily depressed by the one-off charges described above, not because the market is pricing in exceptional growth. P/B is about 2.8x. Whether the stock is actually cheap or expensive hinges on whether profit normalizes back toward its pre-charge run rate in coming quarters - that is not yet knowable.
Growth
Headline growth is muted: full-year FY26 revenue grew just 3.2%. ROCE has nearly halved, from about 23% a year ago to 13% now, which points to margin and profitability pressure rather than clean volume-led expansion. Management's claim of double-digit growth in the base business (excluding lenalidomide) would suggest the underlying volume picture is better than the headline number, but this has not been independently confirmed.
Health
Debt is low and not the concern here - debt-to-equity is around 0.2, with borrowings of about Rs 7,734 crore against equity of about Rs 37,892 crore as of March 2026. The real risk is business/operational: regulatory scrutiny (US FDA Form 483 observations, not warning letters, at three manufacturing sites in 2026), a product recall in Canada, and inventory write-downs tied to new launches. This is execution risk in a complex pipeline, not balance-sheet risk.
Ownership
Promoters hold about 26.6% of the company, with no pledging reported. Domestic institutions (DIIs) hold a larger stake at about 31.9%, with FIIs at about 20.3% - a broad institutional base rather than concentration in one investor type. Not verified: whether any specific well-known individual investor holds a stake; none was confirmed in available sources, so none should be assumed.
The View
The one thing to watch
Whether the Canada semaglutide device relaunch (targeted November 2026) goes through without further recalls, and whether Q3 FY27 profit recovers toward its pre-charge run rate of roughly Rs 1,400+ crore - that will show whether this year's hits were genuinely one-off.
Strengths
- +Low leverage: debt-to-equity of about 0.2, with borrowings of Rs 7,734 crore against equity of Rs 37,892 crore (March 2026)
- +Outperformed both the Nifty and peer Cipla over the last 1 year (-3.3% vs -12.7% and -17.9% respectively)
- +Broad institutional backing, with DIIs holding nearly 32% of the company
- +Management states the base business (excluding the lenalidomide shelf-stock hit) grew in double digits in Q2 FY27 - company's own claim, not independently verified
Watchpoints
- !Net profit has fallen for three consecutive quarters (down 86%, 69% and 35.5% YoY in Q4 FY26, Q1 FY27 and Q2 FY27 respectively), from one-off charges that need to stop recurring for the trend to turn
- !US FDA Form 483 observations recorded at three plants in 2026 (Bachupally twice, Pydibhimavaram) - not warning letters, but worth tracking for any escalation
- !ROCE has nearly halved, from about 23% a year ago to around 13% now
- !Semaglutide relaunch in Canada, targeted for November 2026 after a recall, is a near-term test of execution in a key new product line
How sure are we about the data? · Moderate
Quarterly PAT cross-checked across company filings and financial news (a minor Rs 913 crore vs Rs 925 crore discrepancy for Q2 FY27 was resolved using the company filing figure). EBITDA is not separately disclosed under IFRS filings and was derived from reported margin percentage. Valuation ratios sourced from Screener.in; one outlier P/E figure (155x, from Investing.com) was set aside as likely stale/TTM-distorted. Not verified - check on Screener/company filings: exact litigation settlement amounts, the confirmed Q3 FY27 results date, and the most recent FII/DII stake-change activity.
Keep it for later
Get the Dr. Reddy's Laboratories report as a PDF
The full report, neatly laid out with charts and tables, sent to your inbox. Handy to read offline or share.
Reports are refreshed every quarter, about three days after each company announces its results.
Ticker Tales is not a SEBI-registered investment adviser or research analyst. This report is for learning only and is not investment advice. Data as of 23 Oct 2026.